Condition: mCRPC · Male Urogenital Diseases · Sponsor: The Netherlands Cancer Institute
Radium-223 is an established radionuclide therapy for patients with metastatic castration resistant prostate cancer (mCRPC) and symptomatic bone metastasis. Patients are eligible for this treatment when they have mCRPC and bone metastases; limited extraskeletal lesions (local prostate, lymph nodes \<3 cm) on conventional contrast enhanced CT (ceCT) were allowed in the registration trial(1). Previous research revealed that extraskeletal disease on ceCT and bone scans correlates with a poor response. Meanwhile, 68Ga-PSMA-PET/CT emerged as more sensitive imaging strategy that increases the detection of extraskeletal prostate cancer metastases. It is unclear whether these extraskeletal lesions harbour any predictive value in the treatment of mCRPC patients with Radium-223.
This description comes directly from the study's public registry record.
J.C. van der Mijn, Dr. · +31205129111 · k.vd.mijn@nki.nl
Always discuss trial participation with your own doctor first.
| NKI-AVL | Amsterdam, North Holland, Netherlands | Recruiting |
| Meander Medisch Centrum | Amersfoort, Utrecht, Netherlands | Recruiting |
| Sint Antonius ziekenhuis | Nieuwegein, Utrecht, Netherlands | Recruiting |
| Diakonessenhuis | Utrecht, Netherlands | Not Yet Recruiting |
| UMC | Utrecht, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06659926